Nursing Pharmacology Practice Questions: Chapters 33-34 Bruton Tyrosine Kinase (BTK) Inhibitor: Acalabrutinib (Calquence)

Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapters 33-34 Bruton Tyrosine Kinase (BTK) Inhibitor: Acalabrutinib (Calquence)

Acalabrutinib (Calquence)
1. Irreversible Bruton tyrosine kinase (BTK) Inhibitor
2. Orally bioavailable
3. Both
4. Neither
Acalabrutinib exhibits highest selectivity four:
1. EGFR
2. ITK (interleukin-2-inducible T-cell kinase
3. BTK
Clinical use/uses for Acalabrutinib:
1. Chronic lymphocytic leukemia (CLL)
2. Small lymphocytic leukemia (SLL)
3. Mantle cell lymphoma (MCL)
4. Waldenstrom macroglobulinemia (WM)
5. All of the above
Bruton's tyrosine kinase (BTK):important component of the B-cell receptor (bcr) and cytokine receptor pathways
1. True
2. False
Acalabrutinib:
1. Volume of distribution is about 100 L.
2. Significant human plasma protein binding (about 98%)
3. Both
4. Neither
Acalabrutinib metabolism:
1. Mainly by glutathione conjugation in amide hydrolysis.
2. Mainly by hepatic microsomal P450 enzyme system; mainly by CYP3A isoforms.
3. Both
4. Neither
Primary route of excretion:
1. Feces
2. Urine
3. Both
4. Neither
Acalabrutinib may be clinical used to treat mantle cell lymphoma in adults who have previously received at minimum one prior treatment protocol.
1. True
2. False
Based on animal reproduction studies, in utero acalabrutinib exposure may result in fetal harm.
1. True
2. False
Prominent adverse reactions (>10%) includes/includes:
1. CNS effects
2. Dermatological effects
3. Hematologic/oncologic effects
4. All of the above systems may be adversely affected by acalabrutinib.